Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Momenta Pharmaceuticals Announces CAFC Decision to Invalidate Remanded Teva Pharmaceuticals Patent in Daily COPAXONE(R) 20 mg Suit
Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
Chronic inflammatory demyelinating polyneuropathy following malignant melanoma.
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat.
Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
Treatment selection and experience in multiple sclerosis: survey of neurologists.
Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients.
3D models of human ERα and ERβ complexed with coumestrol.
Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
Genzyme’s Lemtrada Approved in Argentina for Treatment of Multiple Sclerosis
CLARITY – Safety and Efficacy of Oral Cladribine in Subjects with Relapsing-remitting Multiple Sclerosis (MS)
Parent-of-origin effect in multiple sclerosis: observations in half-siblings.
[Epidemiology of multiple sclerosis in the Primosky Krai and Far East regions.]
Physiopathology of symptoms and signs in multiple sclerosis.
SMC Says Yes to Lemtrada(R)a- 1/4 (alemtuzumab) 12mg IV, a New Treatment for Adults with Active Relapsing Remitting-Multiple Sclerosis (RRMS)
Medicare Part D payments for neurologist-prescribed drugs.
The risk of multiple sclerosis in bereaved parents: A nationwide cohort study in Denmark.
Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years.
Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Central motor conduction time may predict response to fampridine in patients with multiple sclerosis.
Santhera enters agreement with Columbia University to investigate additional potential of Catena® in MELAS
Involvement of oxidative stress on the impairment of energy metabolism induced by A beta peptides on PC12 cells: protection by antioxidants.
Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.
[Diagnosis of multiple sclerosis - the 2010 revision of the McDonald criteria.]
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.

Pages